Published: 5 April 2021
Author(s): Fernando Luiz Barros Edington, Sandra Rocha Gadellha, Mittermayer Barreto Santiago
Issue: June 2021

Previously known as SN7618, chloroquine has been used since the early 1940s for the treatment of malaria [1]. In 1946 Loeb F. et al., in a statement approved by the board for coordination of malarial studies, highlighted the efficacy and safety profile of the drug – “with minor side effects as mild and transient headache, visual disturbances, pruritus, and gastrointestinal complaints”. The authors also noted that none of the adverse symptoms was serious and all of them were readily reversible [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.